Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.

The American journal of cardiology - 1 Aug 2010

Baudhuin Linnea M, Miller Wayne L, Train Laura, Bryant Sandra, Hartman Karen A, Phelps Mary, Larock Mary, Jaffe Allan S

Abstract excerpt

The response to beta blockers in patients with heart failure could be associated with the genotype of drug-metabolizing enzymes and/or drug targets. The purpose of the present study was to determine whether specific genetic polymorphisms in ADRB1 (encoding the beta1-adrenergic receptor), CYP2D6,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Carbazoles
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Heart Failure

Share to Metoprolol

Share to Propanolamines

Share to Receptors, Adrenergic, beta-1

Source

Identifiers

PMID: 20643254
DOI: 10.1016/j.amjcard.2010.03.041

Genes

ADRB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20643254-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.PMID 20643254Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Pharmacogenetic factors affecting β-blocker metabolism and response.Semantic proximity Read ↗

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.Semantic proximity Read ↗

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.Semantic proximity Read ↗

Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.Semantic proximity Read ↗

CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.Semantic proximity Read ↗

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.Semantic proximity Read ↗

Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.Semantic proximity Read ↗

Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.Semantic proximity Read ↗

Association between Adrenergic Receptor Genotypes and Beta-Blocker Dose in Heart Failure Patients: Analysis from the HF-ACTION DNA SubstudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.